Andra AP fonden Sells 44,700 Shares of Johnson & Johnson $JNJ

Posted by Stanley Muller on Sep 22nd, 2026

Andra AP fonden lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 11.2% in the second quarter, according to its most recent filing with the SEC. The firm owned 353,177 shares of the company’s stock after selling 44,700 shares during the period. Johnson & Johnson accounts for 1.0% of Andra AP fonden’s portfolio, making the stock its 17th largest position. Andra AP fonden’s holdings in Johnson & Johnson were worth $89,696,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. National Pension Service lifted its holdings in Johnson & Johnson by 1.3% during the 2nd quarter. National Pension Service now owns 5,226,968 shares of the company’s stock valued at $1,327,493,000 after purchasing an additional 67,484 shares during the last quarter. IFP Advisors Inc raised its position in shares of Johnson & Johnson by 8.8% in the second quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock valued at $9,844,000 after purchasing an additional 3,133 shares during the period. Elefante Mark B boosted its holdings in shares of Johnson & Johnson by 9.8% during the 2nd quarter. Elefante Mark B now owns 28,686 shares of the company’s stock worth $7,285,000 after buying an additional 2,563 shares during the period. Signal Advisors Wealth LLC grew its stake in Johnson & Johnson by 76.1% in the 1st quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company’s stock valued at $3,697,000 after buying an additional 6,539 shares during the last quarter. Finally, Gradient Investments LLC raised its holdings in Johnson & Johnson by 9.9% in the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock valued at $38,815,000 after acquiring an additional 13,737 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the transaction, the executive vice president directly owned 23,003 shares in the company, valued at $5,779,963.81. This trade represents a 50.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 87,569 shares of company stock worth $23,064,544. Insiders own 0.16% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Caplyta produced positive Phase 3 results in bipolar mania. J&J said the drug met its primary endpoint, significantly reducing manic symptoms versus placebo by Week 3, with improvement visible as early as Day 3. The result could expand Caplyta beyond its current indications and strengthen the strategic rationale for J&J’s $14.6 billion acquisition of Intra-Cellular Therapies. Regulatory approval and commercial execution remain necessary before the opportunity becomes revenue. Reuters Caplyta bipolar mania study
Positive Sentiment: J&J received European approval for ICOTYDE in plaque psoriasis, adding another potential growth driver to its immunology portfolio and supporting expectations for continued pharmaceutical expansion. EU ICOTYDE approval
Positive Sentiment: Plans to divest the DePuy Synthes orthopedics business are boosting optimism about a more focused J&J. Reports suggest the unit could be sold for roughly $20 billion, allowing J&J to reduce exposure to slower-growing operations, improve profitability and redeploy capital toward higher-growth pharmaceuticals. DePuy Synthes divestiture report
Neutral Sentiment: The Caplyta news is promising but still carries development risk. J&J must obtain regulatory clearance, demonstrate durable benefits and convert the expanded indication into meaningful sales; the trial’s three-week duration does not yet establish longer-term commercial performance. Caplyta expansion path

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Wells Fargo & Company lifted their target price on Johnson & Johnson from $272.00 to $282.00 and gave the stock an “overweight” rating in a report on Monday, August 3rd. Royal Bank Of Canada lifted their price objective on shares of Johnson & Johnson from $265.00 to $287.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Bank of America increased their target price on shares of Johnson & Johnson from $254.00 to $263.00 and gave the stock a “neutral” rating in a research report on Friday, July 10th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $282.00 target price on shares of Johnson & Johnson in a report on Thursday, July 16th. Finally, Weiss Ratings upgraded Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $274.13.

Check Out Our Latest Stock Report on Johnson & Johnson

Johnson & Johnson Price Performance

JNJ stock traded down $1.24 during trading on Tuesday, reaching $268.23. 1,982,335 shares of the company were exchanged, compared to its average volume of 8,022,697. The company has a market capitalization of $646.40 billion, a price-to-earnings ratio of 31.07, a P/E/G ratio of 2.58 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The company has a 50-day moving average of $263.99 and a two-hundred day moving average of $246.86. Johnson & Johnson has a twelve month low of $174.83 and a twelve month high of $281.07.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. During the same period last year, the firm posted $2.77 earnings per share. The business’s revenue for the quarter was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities analysts predict that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were issued a $1.34 dividend. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio is presently 62.11%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.